Essential Thrombocythemia Industry- Regional Synopsis
North America Statistics
North America industry is predicted to dominate majority revenue share of 35% by 2037. The market growth in the region is mostly driven by the rising count of people living with ET. In the United States, the average yearly prevalence of newly detected cases of ET for every ethnic group and race is roughly 2.2 per 100,000 population. Furthermore, the higher investment influx and development of biotech and pharmaceutical sectors are further driving the industry expansion in North America. Since, ET requires long-term management, often with the use of medication and these medications rely on the availability of high-quality active pharmaceutical ingredients (API), raw materials, and antibiotics. The Department of Health and Humans services invested USD 40 million to drive the growth of biopharmaceuticals in the United States.
European Market Forecast
The European essential thrombocythemia market is expected to be the second largest, with a share of around 24% by the end of 2037. According to the European Commission, by December 2021, European Union-based enterprises have raised their investments in health research and development by up to 10.3%. Increased investment in health R&D enables researchers to gain a deeper understanding of ET, including its underlying causes, mechanism, and risk factors. This knowledge contributes to the development of more personalized therapies for ET.
